On July 30, AKESO fell 3.29% in regular trading, trading at 92.4 HKD/share, with turnover of 3.27 billion HKD. The decline reflects continued pressure from a share option exercise price inversion and broad weakness across the biotech sector.

On the news front, the company announced on July 26 the grant of 3,603,500 share options at an exercise price of 99.50 HKD to 167 grantees, alongside 1,648,500 restricted share units to 162 grantees. With the current stock price now well below the 99.50 HKD exercise price, the market perceives short-term dilution risk and sentiment pressure from the inverted pricing. The stock had previously surged nearly 6% on July 23 following an update to ivonescimab global Phase III overall survival data showing consistent efficacy across Western and Eastern populations, but has since pulled back over multiple consecutive sessions.

Meanwhile, the broader biotech sector is under significant selling pressure, with peers including REMEGEN down 5.68%, SKB BIO down 5.10%, INNOVENT BIO down 3.96%, 3SBIO down 2.97%, and BEIGENE down 2.81%, amplifying the downward momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)